List of Excipients in Branded Drug KEPPRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	KEPPRA	levetiracetam	16590-134	CROSCARMELLOSE SODIUM
STAT RX USA LLC	KEPPRA	levetiracetam	16590-134	FERRIC OXIDE YELLOW
STAT RX USA LLC	KEPPRA	levetiracetam	16590-134	MAGNESIUM STEARATE
STAT RX USA LLC	KEPPRA	levetiracetam	16590-134	POLYETHYLENE GLYCOL 3350
STAT RX USA LLC	KEPPRA	levetiracetam	16590-134	POLYETHYLENE GLYCOL 6000
STAT RX USA LLC	KEPPRA	levetiracetam	16590-134	POLYVINYL ALCOHOL

KEPPRA Excipient Strategy and Commercial Opportunities for Levetiracetam Products

Last updated: August 25, 2026

KEPPRA is an established levetiracetam brand with extensive generic competition, limited immediate-release patent protection, and a mature excipient supply chain. The strongest commercial opportunities are in pediatric taste optimization, preservative-free oral liquids, orally disintegrating tablets, low-cost global formulations, ready-to-use intravenous products, and excipient systems that simplify manufacturing while preserving bioequivalence.

What is KEPPRA and which formulations use levetiracetam?

KEPPRA contains levetiracetam, an antiepileptic drug marketed by UCB Pharma. The product is available in immediate-release tablets, oral solution, and intravenous injection. KEPPRA XR is an extended-release tablet formulation.

Product	Dosage form	Typical strengths or concentration	Main commercial use
KEPPRA immediate release	Film-coated tablet	250, 500, 750, 1,000 mg	Adult and adolescent epilepsy
KEPPRA oral solution	Oral liquid	100 mg/mL	Pediatric, geriatric, and swallowing-impaired patients
KEPPRA injection	Intravenous solution	100 mg/mL	Hospital seizure treatment and oral-to-IV substitution
KEPPRA XR	Extended-release tablet	500 and 750 mg	Once-daily maintenance therapy

Levetiracetam has high aqueous solubility and high oral bioavailability. The immediate-release product therefore does not require a sophisticated solubilization platform. Excipient selection is driven mainly by tablet manufacturability, taste, physical stability, preservative control, patient acceptability, and dosage-form differentiation rather than by active-ingredient solubility enhancement (UCB, 2023a; U.S. Food and Drug Administration, 2023a).

What excipients are used in KEPPRA tablets?

KEPPRA immediate-release tablets use a conventional direct-compression or dry-granulation excipient system. The U.S. prescribing information identifies the principal inactive ingredients as croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, povidone, polyethylene glycol, talc, and titanium dioxide, with coating materials used for the film layer (UCB, 2023a).

Excipient category	KEPPRA tablet example	Functional role
Superdisintegrant	Croscarmellose sodium	Promotes rapid tablet breakup
Binder	Povidone K90	Improves granule and tablet strength
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate	Reduces sticking and ejection force
Film-coating components	Polyethylene glycol, talc, titanium dioxide and related coating materials	Protects tablet, improves appearance and handling
Opacifier or pigment	Titanium dioxide	Controls tablet appearance and light protection

The formulation is commercially replicable because it uses widely available compendial excipients. Generic manufacturers can generally avoid dependence on a proprietary excipient technology. The main development risk is not ingredient availability. It is achieving equivalent dissolution, hardness, friability, coating performance, and impurity control across strengths.

How does the KEPPRA tablet excipient system affect generic development?

For immediate-release levetiracetam tablets, the excipient strategy should prioritize:

1. Rapid and reproducible disintegration.
2. Low sensitivity to lubricant overmixing.
3. Consistent content uniformity across 250 mg and 1,000 mg strengths.
4. Robust film coating that supports product identification.
5. Low-cost supply from multiple qualified vendors.
6. Compatibility with high-speed tablet compression.

Because levetiracetam is administered at relatively high doses, low-dose content-uniformity challenges are less severe than for potent drugs. The high drug load, however, can constrain tablet size and reduce formulation flexibility. Compressibility and tablet swallowability become important commercial factors, particularly for the 1,000 mg strength.

What excipients are used in KEPPRA oral solution?

KEPPRA oral solution contains levetiracetam at 100 mg/mL. The labeled excipients include sodium citrate, citric acid monohydrate, methylparaben, propylparaben, ammonium glycyrrhizate, glycerin, maltitol, acesulfame potassium, grape flavor, and purified water (UCB, 2023a).

Excipient	Commercial purpose
Sodium citrate and citric acid	Buffering and pH control
Methylparaben and propylparaben	Antimicrobial preservation
Glycerin	Humectancy, mouthfeel, viscosity
Maltitol	Sweetness and body without sucrose
Acesulfame potassium	High-intensity sweetness
Ammonium glycyrrhizate	Flavor modification and bitterness reduction
Grape flavor	Patient acceptability
Purified water	Vehicle

The oral solution is the most attractive excipient-led opportunity in the KEPPRA franchise. Levetiracetam has a bitter pharmaceutical taste, and pediatric adherence depends on flavor, aftertaste, viscosity, dosing convenience, and caregiver acceptance. A generic product that matches the labeled concentration but performs poorly in taste testing can lose share despite regulatory approval.

What formulation opportunities exist for levetiracetam oral liquids?

Commercial opportunities include:

• Preservative-free multidose or unit-dose oral solution.
• Improved bitterness suppression using ion-pairing, polymeric taste blockers, or multiparticulate barriers.
• Lower-viscosity formulations for oral syringes and feeding tubes.
• Sugar-free and low-calorie formulations.
• Alcohol-free formulations for pediatric use.
• Ready-to-administer unit-dose cups or oral syringes.
• More stable formulations for hot and humid markets.
• Flavors tailored to regional preferences.
• Pediatric formulations with reduced excipient burden.

A preservative-free formulation can command a premium in hospitals, pediatric clinics, and specialty pharmacies, but it requires stronger microbiological control, validated packaging, and often a shorter in-use period. The commercial value depends on whether the product is sold as a multidose bottle, unit-dose package, or ready-to-use oral syringe.

What excipients are used in KEPPRA injection?

KEPPRA injection is a 100 mg/mL intravenous solution. Its listed inactive ingredients include sodium chloride, sodium acetate trihydrate, glacial acetic acid, and water for injection. The product is supplied in single-dose vials and is intended for intravenous use when oral administration is temporarily unavailable (UCB, 2023b).

The injection excipient system is simple. Its development priorities are:

• pH control.
• Osmolality and tolerability.
• Low particulate burden.
• Container-closure compatibility.
• Sterility assurance.
• Stability during dilution.
• Compatibility with common infusion fluids.
• Reliable supply of pharmaceutical-grade raw materials.

The main commercial opportunity is operational rather than molecular. Hospitals may value premixed bags, ready-to-use syringes, or reduced-preparation systems that lower pharmacy labor and medication-error risk. These products can compete on total treatment cost even when the active ingredient is generic.

What patent protection covers KEPPRA and levetiracetam?

The core levetiracetam composition and immediate-release product patents are no longer the principal commercial barrier in the U.S. Generic immediate-release levetiracetam has been marketed for many years. The relevant IP risks now concentrate on dosage form, manufacturing process, device, packaging, and method-of-use claims.

IP area	Current commercial relevance
Core levetiracetam compound	Low for U.S. generic entry
Immediate-release tablet	Low, with extensive generic competition
Oral solution	Generally low at the active-ingredient level; formulation and packaging claims may remain relevant
Intravenous solution	Low for the basic active ingredient; manufacturing and presentation claims may matter
Extended-release tablet	Higher technical and formulation complexity
Taste-masked or orally disintegrating products	Potentially meaningful if protected by valid formulation claims
Device and packaging	Potentially relevant for prefilled syringes and unit-dose systems
Manufacturing process	Relevant where claims cover crystallization, particle control, or impurity reduction

The Orange Book must be reviewed product by product because listed patents can differ between immediate-release KEPPRA, KEPPRA XR, and later presentations. ANDA applicants also must assess non-Orange Book patent risks, including process patents, trade secrets, regulatory exclusivity, and contractual restrictions (U.S. Food and Drug Administration, 2023b).

When did KEPPRA lose exclusivity and what is the Paragraph IV risk?

Immediate-release levetiracetam has already passed the primary U.S. generic-entry phase. FDA-approved generic products from multiple manufacturers have materially reduced the protection available to the original KEPPRA tablet franchise (U.S. Food and Drug Administration, 2023c).

Paragraph IV risk is therefore more relevant to new levetiracetam products than to the established immediate-release tablet:

• A new extended-release formulation may face formulation-patent litigation.
• A taste-masked oral solution may trigger claims covering excipient ratios, taste-masking agents, or manufacturing steps.
• A new delivery device may face combination-product or device patent claims.
• A 505(b)(2) product may encounter method-of-use, formulation, or labeling patents.
• A generic applicant can challenge listed patents through an ANDA Paragraph IV certification.

For a conventional immediate-release tablet, the principal risk is usually regulatory execution and price erosion rather than originator patent litigation.

What is the FDA regulatory status of KEPPRA generics?

Levetiracetam immediate-release tablets, oral solution, and injection are conventional generic opportunities subject to ANDA requirements where the reference product and dosage form are suitable for the pathway. Applicants must demonstrate pharmaceutical equivalence and bioequivalence, comply with current good manufacturing practice, and meet labeling and quality requirements (U.S. Food and Drug Administration, 2023c).

Extended-release products can require more extensive formulation development. Release profiles, food effects, dose dumping, alcohol interaction, and in vitro-in vivo relationships can create additional approval risk. A product that uses a different release-control matrix may be legally permissible but still require substantial development work.

FDA excipient considerations include:

• Use of compendial ingredients where possible.
• Compliance with inactive-ingredient precedent for the route and dosage form.
• Justification for novel excipients or new levels.
• Control of elemental impurities.
• Microbial limits for oral liquids.
• Extractables and leachables for liquid and parenteral packaging.
• Nitrosamine and degradation-product assessment.
• Compatibility with nasogastric and enteral feeding tubes.

How strong is the KEPPRA patent estate?

The patent estate is weak for conventional immediate-release levetiracetam products and stronger for differentiated delivery systems.

A practical risk ranking is:

Product concept	Patent strength	Development barrier	Commercial attractiveness
Standard immediate-release tablet	Low	Low	Moderate, volume-driven
Standard oral solution	Low to moderate	Moderate	High in pediatric and institutional channels
Preservative-free oral solution	Moderate	Moderate to high	High if clinically differentiated
Taste-masked pediatric liquid	Moderate to high	High	High
Standard IV vial	Low	Moderate	Moderate
Premixed IV bag	Moderate	High	High in hospitals
Orally disintegrating tablet	Moderate	Moderate	Moderate to high
Extended-release tablet	Moderate to high	High	Moderate, depending on reimbursement
Novel device or delivery system	Variable	High	Potentially high

The strongest defensible position usually comes from a combination of formulation know-how, clinical usability data, packaging, and manufacturing controls. A narrow patent on a common sweetener system is less durable than a patent supported by taste-performance data, stability results, and a defined excipient ratio.

Which companies are challenging or competing with KEPPRA?

Competition comes from generic manufacturers, specialty pharmaceutical companies, hospital suppliers, and formulation developers. Major generic competition has historically included large ANDA manufacturers such as Teva, Sandoz, Lupin, Dr. Reddy's, Sun Pharma, and Amneal, although the active supplier set varies by dosage form, market, and time.

The commercial landscape has four segments:

Commodity immediate-release generics

These products compete on acquisition cost, manufacturing reliability, wholesaler access, and shortage performance. Excipient differentiation has little value unless it improves production yield or reduces quality deviations.

Pediatric and adherence-focused products

These products compete on palatability, dosing devices, preservative profile, and caregiver convenience. Excipient strategy has direct commercial value.

Hospital injectable products

Competition centers on vial price, premixed presentations, dilution requirements, inventory management, and supply continuity. Packaging and ready-to-use formats can matter more than the basic inactive ingredients.

Extended-release products

These compete on once-daily dosing, adherence, payer coverage, and substitution dynamics. The release-control technology creates more room for intellectual property and product differentiation.

What licensing deals and commercial partnerships are relevant?

UCB retains the KEPPRA brand and has used regional commercial arrangements for certain products and markets. Generic levetiracetam is typically commercialized through standard ANDA ownership, contract manufacturing, supply agreements, and distributor relationships rather than high-value originator licensing.

The most commercially relevant licensing opportunities are likely to involve:

• Taste-masking platforms.
• Pediatric oral-liquid technologies.
• Ready-to-use sterile packaging.
• Extended-release matrix systems.
• Oral syringe and unit-dose packaging.
• Excipient supplier agreements with dual sourcing.
• Regional rights for emerging markets.
• Contract development and manufacturing of hospital presentations.

For an excipient company, licensing a complete formulation platform is more defensible than selling a single commodity ingredient. A package that combines excipient composition, manufacturing process, sensory data, and stability data can support milestone payments, minimum-volume commitments, or preferred-supplier status.

What generic launch scenarios exist for new KEPPRA products?

Low-price immediate-release launch

This strategy targets pharmacy and wholesaler volume. Success depends on manufacturing cost, reliable supply, and avoidance of quality failures. A conventional excipient system is usually optimal.

Premium pediatric liquid launch

This strategy uses improved taste, oral-syringe compatibility, and preservative reduction. It can support a higher price but requires evidence that caregivers and patients prefer the product.

Hospital conversion launch

A ready-to-use IV bag or prefilled syringe can target pharmacy labor, administration time, and inventory reduction. The principal barriers are sterile manufacturing, packaging validation, and hospital formulary adoption.

Specialty extended-release launch

This strategy targets once-daily dosing and adherence. It carries higher formulation and patent risk but may create greater product differentiation than another immediate-release tablet.

What geographic opportunities exist for levetiracetam excipient products?

The U.S. and Western European immediate-release tablet markets are mature and price competitive. Growth opportunities are stronger in:

• Pediatric oral liquids in countries with expanding epilepsy diagnosis and treatment.
• Hospital injections in markets with improving emergency-care infrastructure.
• Unit-dose liquid packaging in regulated markets.
• Stable formulations for tropical climates.
• Low-cost, locally sourced excipient systems in emerging markets.
• Products compatible with enteral feeding systems.
• Preservative-free presentations for institutional use.

Regulatory requirements vary. An excipient accepted in the U.S. may not have the same precedent in every jurisdiction. Global developers should select excipients with broad pharmacopeial status and established route-of-administration history.

What manufacturing and IP barriers affect KEPPRA formulation opportunities?

The main barriers are practical:

• Achieving acceptable taste without increasing viscosity excessively.
• Maintaining oral-liquid preservative efficacy.
• Preventing precipitation or pH drift.
• Controlling microbial growth in multidose packaging.
• Producing high-dose tablets with acceptable size and hardness.
• Preserving dissolution after scale-up.
• Maintaining sterile quality in ready-to-use IV presentations.
• Demonstrating compatibility with infusion systems and feeding tubes.
• Protecting the product against excipient or packaging supply interruptions.

Trade secrets can be important even where patent protection is limited. Flavor ratios, order of addition, mixing energy, pH adjustment, filtration conditions, and packaging headspace may materially affect product performance. These process controls can create commercial barriers without appearing in the Orange Book.

What is the revenue exposure for KEPPRA-related products?

UCB does not generally disclose a separate current revenue line for every KEPPRA formulation in public financial reporting. Brand revenue exposure has declined because immediate-release levetiracetam faces broad generic substitution. Commercial value remains in several areas:

• Branded KEPPRA and KEPPRA XR where substitution is limited.
• Hospital injectable supply.
• Pediatric oral solution.
• Regional markets with lower generic penetration.
• Formulation platforms licensed to generic or specialty manufacturers.
• Excipient and packaging supply contracts tied to differentiated products.

For investors and licensors, the relevant metric is not historical KEPPRA revenue alone. It is the addressable value of differentiated levetiracetam presentations, gross margin after manufacturing complexity, and the ability to defend the product through formulation, packaging, regulatory, or process IP.

Key Takeaways

• KEPPRA is a mature levetiracetam franchise with low patent barriers for conventional immediate-release tablets.
• The tablet excipient system is conventional and offers limited differentiation beyond manufacturing efficiency.
• The oral solution offers the strongest excipient-led opportunity because taste, preservation, viscosity, and dosing convenience affect adherence.
• Preservative-free, taste-masked, unit-dose, and feeding-tube-compatible liquids have higher commercial potential than another standard generic liquid.
• Ready-to-use intravenous presentations can compete through pharmacy labor savings and reduced preparation risk.
• KEPPRA XR and other extended-release products have higher formulation and patent complexity.
• The strongest commercial IP positions combine excipient composition, process control, sensory performance, packaging, and stability data.
• Generic launch risk is driven primarily by price erosion, supply reliability, bioequivalence, and manufacturing execution for immediate-release products.
• UCB brand revenue is difficult to isolate by formulation, but generic erosion limits the value of an undifferentiated KEPPRA copy.
• Excipient suppliers should pursue platform licensing, dual-source supply agreements, and co-development with generic or specialty manufacturers.

FAQs About KEPPRA Excipients and Commercial Strategy

Can a generic levetiracetam oral solution use different excipients from KEPPRA?

Yes. A generic may use different inactive ingredients if it satisfies FDA requirements for safety, pharmaceutical equivalence, bioequivalence, stability, quality, and labeling.

Is taste masking patentable for levetiracetam?

It can be. Patentability depends on the specific taste-masking agent, concentration range, dosage form, process, performance data, and whether the claims are novel and non-obvious.

Does KEPPRA contain lactose?

The U.S. KEPPRA tablet inactive-ingredient listing does not identify lactose as a principal excipient. Product labels should be checked by jurisdiction and presentation because formulations can differ internationally.

Which levetiracetam dosage form has the greatest commercial opportunity?

A differentiated pediatric oral liquid has the strongest excipient-driven opportunity. A ready-to-use IV product can also be attractive in hospitals, but sterile manufacturing and packaging costs are higher.

Can levetiracetam be formulated as an orally disintegrating tablet?

Yes. The high dose creates tablet-size and taste challenges, but superdisintegrants, porous matrices, flavor systems, and taste-masking technologies can support an orally disintegrating presentation.

References

1. UCB, Inc. (2023a). KEPPRA (levetiracetam) tablets and oral solution: U.S. prescribing information. U.S. Food and Drug Administration.

2. UCB, Inc. (2023b). KEPPRA (levetiracetam) injection: U.S. prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (2023a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (2023b). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

5. U.S. Food and Drug Administration. (2023c). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm